Australian Pharmaceutical Industries SWOT Analysis
Published in Pharma and Healthcare category by MBA Skool Team
Australian Pharmaceutical Industries is one of the leading brands in the pharma and healthcare sector. Australian Pharmaceutical Industries SWOT analysis evaluates the brand by its strengths & weaknesses which are the internal factors along with opportunities & threats which are the external factors. Let us start the SWOT Analysis of Australian Pharmaceutical Industries:
Offers a broad range of pharmacy services, including wholesale product delivery, retail services, marketing programs and business advisory services
A number of landmark products and banners.
The retail footprint allows for good growth.
Niche player in over-the-counter pharmaceuticals and toiletries
Its subsidiaries include Priceline, Priceline Pharmacy, Soul Pattinson, Pharmacists Advice
Above are the strengths in the SWOT Analysis of Australian Pharmaceutical Industries. The strengths of Australian Pharmaceutical Industries looks at the key internal factors of its business which gives it competitive advantage in the market and strengthens its position.
Australian Pharmaceutical Industries Weaknesses
Alleged accounting discrepancies & Sigma takeover controversies affected the brand
The company may lose focus if they enter into different segments (personal care, well-being products) all together
The market is dominated (90% of market) by 3 major players – API, Sigma, and Symbion Health; gaining more market share is a difficult task
These were the weaknesses in the Australian Pharmaceutical Industries SWOT Analysis. The weaknesses of a brand are certain aspects of its business which it can improve.
Australian Pharmaceutical Industries Opportunities
Awareness about healthcare is rapidly increasing, API has a huge space to come up with healthcare and well-being products
It can divest pharmaceutical assets which could help the company in increasing its focus on core business
There is scope for development in areas of well-being and personal care.
Above we covered the opportunities in Australian Pharmaceutical Industries SWOT Analysis. The opportunities for any brand can include prospects of future growth.
Australian Pharmaceutical Industries Threats
Reforms in pharmaceutical pricing scheme namely PBS reforms can create trouble for the company
The margins of the company may be hurt because of PBS because it may create a trade barrier between Australian and U.S. drug companies
Stringent rules against clinical trials and quality of drugs will require more stringent measures from the company leading to increased costs
The threats in the SWOT Analysis of Australian Pharmaceutical Industries are as mentioned above. The threats for any business can be external factors which can negatively impact its business.
API is Australia's largest wholesale distributor of pharmaceutical and allied products.
Australian Pharmaceutical Industries STP
People who looking for quality drugs for health and beauty purposes.
Healthcare professionals, wholesalers, generic distributors, and hospitals
API is involved in pharmaceutical distribution, retailing and manufacturing of health and beauty products.
This article has been researched & authored by the Content & Research Team. It has been reviewed & published by the MBA Skool Team. The content on MBA Skool has been created for educational & academic purpose only.
Browse marketing analysis of more brands and companies similar to Australian Pharmaceutical Industries. This section covers SWOT Analysis along with Segmentation, Target Market, Positioning & USP of more than 2000 brands from over 20 industry sectors.
The brand names and other brand information used in the SWOT Analysis section are properties of their respective companies. The companies are not associated with MBA Skool in any way. Edit the brand or add a new one to SWOT Analysis section : Contribute